论文部分内容阅读
国家医药管理局天津药物研究院研制成功的抗心律失常新药盐酸莫雷西嗪片,是一种治疗心律失常疗效高、副作用小的国家级新药。经卫生部批准,由东北第六制药厂投入生产,并投放市场。 动物实验证实:该药具有显著的抗快速性心律失常作用,其作用与奎尼丁相似,但对呼吸、血压、心率及心肌收缩力无明显影响。还具有扩张冠状血管、解痉和抗M-胆碱能作用。该药经胃肠道吸收,1～3h后血药浓度达高峰,半衰期3h,主要经肝
Tianjin Pharmaceutical Research Institute of the State Pharmaceutical Administration successfully developed a new antiarrhythmic drug Moresine hydrochloride tablets, is a treatment of arrhythmia efficacy, side effects of small national drug. Approved by the Ministry of Health, it is put into production from the 6th Northeast Pharmaceutical Factory and put on the market. Animal experiments confirmed that the drug has a significant anti-tachyarrhythmia role similar to quinidine, but no significant effect on respiration, blood pressure, heart rate and myocardial contractility. Also has the expansion of coronary vessels, antispasmodic and anti-M-cholinergic effect. The drug absorbed by the gastrointestinal tract, 1 ~ 3h after the peak plasma concentration, half-life of 3h, the main liver